All codes
G390
G390 – Supervision of chemotherapy, biologic agent infusion, or bispecific antibody infusion
OHIP Diagnostic and Therapeutic Procedures Code — DIAGNOSTIC AND THERAPEUTIC PROCEDURES · Schedule of Benefits
Supervision of chemotherapy for induction phase of acute leukemia or myeloablative therapy prior to bone marrow transplantation (maximum of 1 per induction phase or myeloablative therapy); and/or supervision of biologic agent(s) such as Chimeric Antigen Receptor T-Cell Therapy (CAR-T) infusion (maximum of 1 per infusion); and/or supervision of bispecific antibody infusion, during initial dosing phase, where there is a high risk of cytokine release syndrome (maximum of 3 per initial dosing phase)
The medical record must document the supervision of chemotherapy for the induction phase of acute leukemia or myeloablative therapy prior to bone marrow transplantation to support the claim, as per general medical record requirements outlined in .
maximum of 1 per induction phase or myeloablative therapy
maximum of 1 per infusion (for biologic agent(s) such as Chimeric Antigen Receptor T-Cell Therapy (CAR-T) infusion)
maximum of 3 per initial dosing phase (for bispecific antibody infusion, where there is a high risk of cytokine release syndrome)
Ready to bill this code?
SnapBill makes OHIP billing simple — auto-filled codes, validation, and batch submission.